A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Heart Failure With Reduced Ejection Fraction (HFrEF)

In brief

The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.

Key facts

Study ID

NCT07584967

Run by

AnaCardio AB

People needed

400

Starts

2026-09-15

Expected to finish

2028-06-09

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.